Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 100

1.

BRAF: a tool in the decision to perform elective neck dissection?

Dutenhefner SE, Marui S, Santos AB, de Lima EU, Inoue M, Neto JS, Shiang C, Fukushima JT, Cernea CR, Friguglietti CU.

Thyroid. 2013 Dec;23(12):1541-6. doi: 10.1089/thy.2012.0304. Epub 2013 Nov 12.

PMID:
23186006
2.
3.

Prediction of occult central lymph node metastasis in papillary thyroid carcinoma by preoperative BRAF analysis using fine-needle aspiration biopsy: a prospective study.

Joo JY, Park JY, Yoon YH, Choi B, Kim JM, Jo YS, Shong M, Koo BS.

J Clin Endocrinol Metab. 2012 Nov;97(11):3996-4003. doi: 10.1210/jc.2012-2444. Epub 2012 Aug 28.

PMID:
22930785
4.

The role of molecular markers and tumor histological type in central lymph node metastasis of papillary thyroid carcinoma.

Paulson L, Shindo M, Schuff K, Corless C.

Arch Otolaryngol Head Neck Surg. 2012 Jan;138(1):44-9. doi: 10.1001/archoto.2011.226.

PMID:
22249628
5.

Does BRAF V600E mutation predict aggressive features in papillary thyroid cancer? Results from four endocrine surgery centers.

Li C, Aragon Han P, Lee KC, Lee LC, Fox AC, Beninato T, Thiess M, Dy BM, Sebo TJ, Thompson GB, Grant CS, Giordano TJ, Gauger PG, Doherty GM, Fahey TJ 3rd, Bishop J, Eshleman JR, Umbricht CB, Schneider EB, Zeiger MA.

J Clin Endocrinol Metab. 2013 Sep;98(9):3702-12. doi: 10.1210/jc.2013-1584. Epub 2013 Aug 22.

PMID:
23969188
6.

Is BRAF mutation associated with lymph node metastasis in patients with papillary thyroid cancer?

Lee KC, Li C, Schneider EB, Wang Y, Somervell H, Krafft M, Umbricht CB, Zeiger MA.

Surgery. 2012 Dec;152(6):977-83. doi: 10.1016/j.surg.2012.08.019. Epub 2012 Oct 11.

7.

BRAF V600E mutation independently predicts central compartment lymph node metastasis in patients with papillary thyroid cancer.

Howell GM, Nikiforova MN, Carty SE, Armstrong MJ, Hodak SP, Stang MT, McCoy KL, Nikiforov YE, Yip L.

Ann Surg Oncol. 2013 Jan;20(1):47-52. doi: 10.1245/s10434-012-2611-0. Epub 2012 Sep 1.

PMID:
22941165
8.

Association of BRAF V600E Mutation and MicroRNA Expression with Central Lymph Node Metastases in Papillary Thyroid Cancer: A Prospective Study from Four Endocrine Surgery Centers.

Han PA, Kim HS, Cho S, Fazeli R, Najafian A, Khawaja H, McAlexander M, Dy B, Sorensen M, Aronova A, Sebo TJ, Giordano TJ, Fahey TJ 3rd, Thompson GB, Gauger PG, Somervell H, Bishop JA, Eshleman JR, Schneider EB, Witwer KW, Umbricht CB, Zeiger MA.

Thyroid. 2016 Apr;26(4):532-42. doi: 10.1089/thy.2015.0378. Epub 2016 Mar 7.

9.

Ipsilateral versus bilateral central neck lymph node dissection in papillary thyroid carcinoma.

Moo TA, Umunna B, Kato M, Butriago D, Kundel A, Lee JA, Zarnegar R, Fahey TJ 3rd.

Ann Surg. 2009 Sep;250(3):403-8. doi: 10.1097/SLA.0b013e3181b3adab.

PMID:
19661784
10.

Preoperative BRAF mutation is predictive of occult contralateral carcinoma in patients with unilateral papillary thyroid microcarcinoma.

Zhou YL, Zhang W, Gao EL, Dai XX, Yang H, Zhang XH, Wang OC.

Asian Pac J Cancer Prev. 2012;13(4):1267-72.

11.

Optimizing surgical treatment of papillary thyroid carcinoma associated with BRAF mutation.

Yip L, Nikiforova MN, Carty SE, Yim JH, Stang MT, Tublin MJ, Lebeau SO, Hodak SP, Ogilvie JB, Nikiforov YE.

Surgery. 2009 Dec;146(6):1215-23. doi: 10.1016/j.surg.2009.09.011.

PMID:
19958951
12.

Role of BRAF V600E mutation as an indicator of the extent of thyroidectomy and lymph node dissection in conventional papillary thyroid carcinoma.

Kim SK, Woo JW, Lee JH, Park I, Choe JH, Kim JH, Kim JS.

Surgery. 2015 Dec;158(6):1500-11. doi: 10.1016/j.surg.2015.05.016. Epub 2015 Jun 26.

PMID:
26120069
13.

[Invasiveness of papillary thyroid microcarcinoma with BRAF mutation].

Yang X, Liang ZY, Meng C, Liang J, Yu Z, Lin YS.

Zhongguo Yi Xue Ke Xue Yuan Xue Bao. 2013 Aug;35(4):398-403. doi: 10.3881/j.issn.1000-503X.2013.04.008. Chinese.

14.

BRAF mutation testing of thyroid fine-needle aspiration biopsy specimens for preoperative risk stratification in papillary thyroid cancer.

Xing M, Clark D, Guan H, Ji M, Dackiw A, Carson KA, Kim M, Tufaro A, Ladenson P, Zeiger M, Tufano R.

J Clin Oncol. 2009 Jun 20;27(18):2977-82. doi: 10.1200/JCO.2008.20.1426. Epub 2009 May 4.

15.

The BRAF mutation is useful for prediction of clinical recurrence in low-risk patients with conventional papillary thyroid carcinoma.

Kim TY, Kim WB, Rhee YS, Song JY, Kim JM, Gong G, Lee S, Kim SY, Kim SC, Hong SJ, Shong YK.

Clin Endocrinol (Oxf). 2006 Sep;65(3):364-8.

PMID:
16918957
16.

Pre-operative role of BRAF in the guidance of the surgical approach and prognosis of differentiated thyroid carcinoma.

Danilovic DL, Lima EU, Domingues RB, Brandão LG, Hoff AO, Marui S.

Eur J Endocrinol. 2014 Mar 13;170(4):619-25. doi: 10.1530/EJE-13-0944. Print 2014 Apr.

17.
18.

Lymphatic mapping establishes the role of BRAF gene mutation in papillary thyroid carcinoma.

Kim J, Giuliano AE, Turner RR, Gaffney RE, Umetani N, Kitago M, Elashoff D, Hoon DS.

Ann Surg. 2006 Nov;244(5):799-804.

19.

BRAF V600E mutation and p27 kip1 expression in papillary carcinomas of the thyroid <or=1 cm and their paired lymph node metastases.

Rodolico V, Cabibi D, Pizzolanti G, Richiusa P, Gebbia N, Martorana A, Russo A, Amato MC, Galluzzo A, Giordano C.

Cancer. 2007 Sep 15;110(6):1218-26.

20.

[Relationship and clinical significance between mutated BRAF with prophylactic central-neck nodal dissection in papillary thyroid carcinoma].

Zhang YJ, Liu BG, Zhao ZY, Sheng JD, Feng DD.

Beijing Da Xue Xue Bao. 2016 Jun 18;48(3):502-6. Chinese.

Supplemental Content

Support Center